Nebenwirkungen dermatoonkologischer Therapien
Immuncheckpointblocker (ICB) wie PD-(L)1- und CTLA-4-Antikörper sowie zielgerichtete Therapeutika wie BRAF(v-raf murine sarcoma viral oncogene homolog B1)- und MEK(Mitogen-aktivierte Proteinkinase-Kinase)-Inhibitoren haben die systemische Therapie von Hauttumoren in adjuvanter und lokal fortgeschri...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Deutsch |
| Veröffentlicht: |
May 2024
|
| In: |
Die Dermatologie
Year: 2024, Jahrgang: 75, Heft: 6, Pages: 466-475 |
| ISSN: | 2731-7013 |
| DOI: | 10.1007/s00105-024-05354-3 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00105-024-05354-3
|
| Verfasserangaben: | Jessica C. Hassel, Lisa Zimmer |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1927275105 | ||
| 003 | DE-627 | ||
| 005 | 20250602155033.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250602s2024 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00105-024-05354-3 |2 doi | |
| 035 | |a (DE-627)1927275105 | ||
| 035 | |a (DE-599)KXP1927275105 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a ger | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 245 | 1 | 0 | |a Nebenwirkungen dermatoonkologischer Therapien |c Jessica C. Hassel, Lisa Zimmer |
| 246 | 1 | |i Englischsprachiger Titel auf der Frontdoor |a Side effects of dermato-oncologic therapies | |
| 264 | 1 | |c May 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online publiziert: 27. Mai 2024 | ||
| 500 | |a Gesehen am 02.06.2025 | ||
| 520 | |a Immuncheckpointblocker (ICB) wie PD-(L)1- und CTLA-4-Antikörper sowie zielgerichtete Therapeutika wie BRAF(v-raf murine sarcoma viral oncogene homolog B1)- und MEK(Mitogen-aktivierte Proteinkinase-Kinase)-Inhibitoren haben die systemische Therapie von Hauttumoren in adjuvanter und lokal fortgeschrittener Therapiesituation maßgeblich verbessert. All diese Substanzen unterscheiden sich in ihrem Nebenwirkungsspektrum. | ||
| 650 | 4 | |a BRAF inhibitor | |
| 650 | 4 | |a BRAF-Inhibitor | |
| 650 | 4 | |a Dermatological Manifestations | |
| 650 | 4 | |a Dermatological Therapy | |
| 650 | 4 | |a Dermatology | |
| 650 | 4 | |a Immuncheckpointblocker | |
| 650 | 4 | |a Immune checkpoint inhibitor | |
| 650 | 4 | |a MEK inhibitor | |
| 650 | 4 | |a MEK-Inhibitor | |
| 650 | 4 | |a Melanoma | |
| 650 | 4 | |a Skin cancer | |
| 650 | 4 | |a Targeted therapies | |
| 650 | 4 | |a Tebentafusp | |
| 650 | 4 | |a Zielgerichtete Tumortherapie | |
| 700 | 1 | |a Zimmer, Lisa |d 1977- |e VerfasserIn |0 (DE-588)131597914 |0 (DE-627)511279620 |0 (DE-576)298613875 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Die Dermatologie |d [Berlin] : Springer Medizin Verlag GmbH, 2022 |g 75(2024), 6, Seite 466-475 |h Online-Ressource |w (DE-627)1808047648 |w (DE-600)3122900-1 |x 2731-7013 |7 nnas |a Nebenwirkungen dermatoonkologischer Therapien |
| 773 | 1 | 8 | |g volume:75 |g year:2024 |g number:6 |g pages:466-475 |g extent:10 |a Nebenwirkungen dermatoonkologischer Therapien |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00105-024-05354-3 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250602 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |d 50000 |e 910000PH129790702 |e 911300PH129790702 |e 50000PH129790702 |k 0/910000/ |k 1/910000/911300/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1927275105 |e 4729932269 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1927275105","physDesc":[{"extent":"10 S.","noteIll":"Illustrationen"}],"origin":[{"dateIssuedDisp":"May 2024","dateIssuedKey":"2024"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"1808047648","disp":"Nebenwirkungen dermatoonkologischer TherapienDie Dermatologie","origin":[{"dateIssuedDisp":"[2022]-","publisherPlace":"[Berlin]","publisher":"Springer Medizin Verlag GmbH"}],"pubHistory":["Volume 73, issue 7 (July 2022)-"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["ger","eng"],"note":["Gesehen am 28.06.2022","Erscheint monatlich"],"id":{"zdb":["3122900-1"],"issn":["2731-7013"],"eki":["1808047648"]},"part":{"year":"2024","volume":"75","pages":"466-475","issue":"6","text":"75(2024), 6, Seite 466-475","extent":"10"},"title":[{"subtitle":"Zeitschrift für Dermatologie, Venerologie und verwandte Gebiete","title":"Die Dermatologie","title_sort":"Dermatologie"}]}],"person":[{"given":"Jessica C.","role":"aut","family":"Hassel","display":"Hassel, Jessica C."},{"family":"Zimmer","role":"aut","given":"Lisa","display":"Zimmer, Lisa"}],"title":[{"title":"Nebenwirkungen dermatoonkologischer Therapien","title_sort":"Nebenwirkungen dermatoonkologischer Therapien"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["ger"],"note":["Online publiziert: 27. Mai 2024","Gesehen am 02.06.2025"],"name":{"displayForm":["Jessica C. Hassel, Lisa Zimmer"]},"titleAlt":[{"title":"Side effects of dermato-oncologic therapies"}],"id":{"doi":["10.1007/s00105-024-05354-3"],"eki":["1927275105"]}} | ||
| SRT | |a HASSELJESSNEBENWIRKU2024 | ||